Chaperonin 10 immunosuppression
The invention is directed to the use of cpn10 in transplantation and particularly to treatment and/or prevention of graft versus host disease. The invention provides a method of administration of cpn10 to a donor and/or recipient animal or cells, tissues or organs derived from the donor, although in a particularly advantageous form treatment of both the donor and recipient animal. The method may further include the administration to the donor and/or recipient animal at least one other immunosuppressive agent to prevent or alleviate graft versus host disease.
1. A method of treating graft versus host disease (GVHD), said method comprising
administering to a mammalian recipient a pharmaceutically-effective amount of chaperonin 10 (cpn10) comprising the amino acid sequence set forth in FIG. 1 (SEQ ID NO:1).
2. The method of claim 1 wherein the pharmaceutically-effective amount of cpn10 administered to the mammalian recipient is within the range 0.1-100 mg/kg body weight.
3. The method of claim 2 wherein the pharmaceutically-effective amount of cpn10 administered to the mammalian recipient is within the range 0.1-10 mg/kg body weight.
4. The method of claim 1 further comprising administering to said mammalian recipient at least one other immunosuppressive agent selected from the group consisting of cyclosporin, tacrolimus, sirolimus, mycophenolate mofetil and methotrexate.
5. The method of claim 1 further comprising administering a steroid to the mammalian recipient.
6. The method of claim 1 wherein the cpn10 is administered in a pharmaceutical composition.